You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


Clinical Trials x

At the General Meeting of the American Society of Clinical Oncology (ASCO) in June , BCRF researcher, Dr. Monica Bertagnolli, was named as the organization’s 2018 President-Elect.

HER2-positive breast cancer

Once a disease with poor prognosis, HER2-positive breast cancer is now a very treatable breast cancer. In early stage HER2 breast cancer, the challenge facing clinicians is selecting the most efficacious therapy from the many options available.

The care a patient receives during and after cancer is based on clinical evidence obtained through precisely conducted clinical trials known as randomized controlled trials (RCT).

It’s been an exciting week at AACR. Here are a few highlights from clinical trials in breast cancer reported at Monday’s session.


​​A Presurgery Combination Therapy May Improve Outcomes for Women With HER2-positive Breast Cancer

A major challenge in identifying ways to improve breast health is lack of participation in clinical trials.

The 37th annual San Antonio Breast Cancer Symposium (SABCS) took place on December 9-13. The annual five-day program provides a forum for communication and education in breast cancer research.

Here at BCRF, we work hard to find and fund the most innovative minds in breast cancer research. Longstanding grantees Drs.